Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05705466 | Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and… | Phase 1 / Phase 2 | withdrawn | Jan 30, 2023 | Kartos Therapeutics, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04396340 | First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to… | Phase 1 | terminated | May 20, 2020 | Mersana Therapeutics | discontinued development program | Other (stated, no rule matched) |
| NCT04610684 | Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer… | Phase 2 | terminated | Oct 30, 2020 | Jeffrey Clarke | Lack of Enrollment | Enrollment / accrual |
| NCT01953926 | Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or…(SUMMIT) | Phase 2 | terminated | Oct 1, 2013 | Puma Biotechnology, Inc. | The study was terminated to align with the sponsor's current development plans for neratinib. The… | Safety / toxicity |
| NCT04102436 | Non-Viral TCR Gene Therapy | Phase 2 | withdrawn | Sep 25, 2019 | National Cancer Institute (NCI) | Difficulty with availability of GLP-grade reagents for manufacturing. | Drug supply |
| NCT04923802 | Multi-Omics Testing for Immunotherapy Efficacy Evaluation (MOTIVATION)(MOTIVATION) | — | terminated | Jun 11, 2021 | GeneCast Biotechnology Co., Ltd. | Unable to recruit sufficient numbers of patients | Enrollment / accrual |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2… | Phase 1 | terminated | Nov 16, 2021 | HiberCell, Inc. | sponsor decision | Sponsor / business decision |
| NCT04352413 | A Study of PLM60 in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based… | Phase 2 | terminated | Apr 20, 2020 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | The sponsor has adjusted its R\&D strategy. | Sponsor / business decision |
| NCT04816214 | Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in…(GEOMETRY-E) | Phase 3 | terminated | Mar 25, 2021 | Novartis Pharmaceuticals | Novartis decided to terminate the study based on a business consideration and not related with any… | Safety / toxicity |
| NCT06052423 | ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | withdrawn | Sep 25, 2023 | Hansoh BioMedical R&D Company | Research and development strategy adjustment. | Sponsor / business decision |
| NCT05099549 | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in… | Phase 1 / Phase 2 | terminated | Oct 29, 2021 | NKGen Biotech, Inc. | Affimed and NKGen have mutually decided to discontinue the study. Affimed will evaluate the best… | Other (stated, no rule matched) |
| NCT03190239 | Efficacy and Safety of Maintenance Apatinib Combined With Pemetrexed in Advanced…(XQonc-007) | Phase 2 | withdrawn | Jun 16, 2017 | Xinqiao Hospital of Chongqing | abandon | Other (stated, no rule matched) |
| NCT03257722 | Pembrolizumab + Idelalisib for Lung Cancer Study(PIL) | Phase 1 / Phase 2 | terminated | Aug 22, 2017 | Asha Nayak | The study was terminated due to poor accrual. | Enrollment / accrual |
| NCT03792503 | Pemetrexed Plus Apatinib Maintenance Treatment in Patients With Non-squamous Non-small… | Phase 4 | withdrawn | Jan 3, 2019 | Xinqiao Hospital of Chongqing | abandon | Other (stated, no rule matched) |
| NCT04491084 | FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy(FLT3) | Phase 1 / Phase 2 | terminated | Jul 29, 2020 | Albert Einstein College of Medicine | Low accrual | Enrollment / accrual |
| NCT03818776 | Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC | Early Phase 1 | terminated | Jan 28, 2019 | Case Comprehensive Cancer Center | Safety | Safety / toxicity |
| NCT02654587 | OSE2101 Versus Chemotherapy in HLA-A2 Positive Patients With Advanced NSCLC After Immune…(ATALANTE-1) | Phase 3 | terminated | Jan 13, 2016 | OSE Immunotherapeutics | due to COVID-19 | COVID-19 / pandemic |
| NCT04676386 | Biomarker Analysis in High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1 Based…(BEACON-LUNG) | — | terminated | Dec 21, 2020 | Addario Lung Cancer Medical Institute | Recruitment futility | Efficacy / futility |
| NCT00617656 | Study to Evaluate Treatment Customized According to RAP80 and BRCA1 in Patients With…(BREC) | Phase 3 | terminated | Feb 18, 2008 | Spanish Lung Cancer Group | No safety reasons. Interim analysis shows that the hypothesis superiority of the experimental arm… | Safety / toxicity |
| NCT05176925 | Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent… | Phase 2 | terminated | Jan 4, 2022 | Fudan University | The trial was terminated per sponsor recommendation | Other (stated, no rule matched) |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | Phase 1 | terminated | Jul 18, 2019 | Kite, A Gilead Company | The sponsor finds the risk/benefit analysis unfavorable and has terminated the study. | Other (stated, no rule matched) |
| NCT04524195 | PET Imaging With [18F]F-AraG in Advanced Non-small Cell Lung Cancer (NSCLC) | Phase 1 | terminated | Aug 24, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study is terminated because the PI left the institution. | Investigator |
| NCT03840902 | M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | terminated | Feb 15, 2019 | EMD Serono Research & Development Institute, Inc. | Based on recommendations by an external Independent data Monitoring Committee (IDMC), Sponsor… | Efficacy / futility |
| NCT05088967 | Efficacy and Safety of IBI110 in Combination With Sintilimab Versus Sintilimab Alone in… | Phase 1 | terminated | Oct 22, 2021 | Innovent Biologics (Suzhou) Co. Ltd. | Development strategy adjustment | Sponsor / business decision |
| NCT03492801 | Collection of Blood Samples in Patients With Non-small Cell Lung Cancer | — | terminated | Apr 10, 2018 | University of Southern California | Insufficient accrual | Enrollment / accrual |
| NCT03870529 | High Dose Vitamin A Compound in Treating Participants With Resectable Non-Small Cell Lung… | Early Phase 1 | terminated | Mar 12, 2019 | Wake Forest University Health Sciences | Slow accruals | Enrollment / accrual |
| NCT03149549 | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug… | Phase 1 / Phase 2 | terminated | May 11, 2017 | CytomX Therapeutics | Covid Pandemic; Business Decision to separate Phase 2 to new study | COVID-19 / pandemic |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | Phase 1 | terminated | Jan 28, 2020 | Atreca, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | Phase 1 | terminated | Dec 5, 2019 | University of Florida | Sponsor terminated | Other (stated, no rule matched) |
| NCT04099836 | Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease… | Phase 2 | terminated | Sep 23, 2019 | Duke University | low accrual | Enrollment / accrual |
| NCT03499678 | Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA | — | terminated | Apr 17, 2018 | HKGepitherapeutics | Encountered technical issues with blood plasma samples received from the hospital. | Other (stated, no rule matched) |
| NCT04870034 | Binimetinib and Palbociclib Before Surgery for the Treatment of Operable KRAS-Positive… | Early Phase 1 | withdrawn | May 3, 2021 | Roswell Park Cancer Institute | Issues recruiting | Enrollment / accrual |
| NCT05465590 | A Phase 1 Study to Evaluate Paclitaxel Conjugated CXC Receptor 4 Antagonist (MB1707) in… | Early Phase 1 | withdrawn | Jul 20, 2022 | Mainline Biosciences, Inc. | The study was terminated due to Sponsor decision | Sponsor / business decision |
| NCT01514864 | Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or… | Phase 2 | terminated | Jan 23, 2012 | Bristol-Myers Squibb | Lack of efficacy and slow accrual | Efficacy / futility |
| NCT02531854 | A Study of Pemetrexed Maintenance With or Without ADXS11-001 Immunotherapy in Patients… | Phase 2 | withdrawn | Aug 25, 2015 | Advaxis, Inc. | Study was withdrawn per sponsor decision | Sponsor / business decision |
| NCT03386929 | Survival Prolongation by Rationale Innovative Genomics(SPRING) | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | Worldwide Innovative Network Association | The SPRING trial had to be early terminated at the end of the Phase 1 portion of the study due to… | Funding |
| NCT05948462 | Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic…(NSCLC) | Phase 2 | withdrawn | Jul 17, 2023 | SCRI Development Innovations, LLC | Study withdrawn by pharmaceutical funding partner | Funding |
| NCT02649673 | LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and… | Phase 1 | terminated | Jan 7, 2016 | SCRI Development Innovations, LLC | Clinical program was discontinued by Novartis | Other (stated, no rule matched) |
| NCT05421936 | Osimertinib for NSCLC With Uncommon EGFR Mutations(UNICORN) | — | suspended | Jun 16, 2022 | Sheba Medical Center | Result summarized and published | Other (stated, no rule matched) |
| NCT04785365 | Long-Term Follow-Up Study of Patients Receiving ATL001 | Phase 2 | terminated | Mar 5, 2021 | Achilles Therapeutics UK Limited | The long-term follow-up of patients is being migrated to the original (parent) study protocols… | Other (stated, no rule matched) |
| NCT04556435 | Breath Analysis in Early Stage Lung Cancer Using Infrared Spectroscopy | — | terminated | Sep 21, 2020 | Breathe BioMedical Inc | Change in the sponsor's business strategy (new focus on breast cancer) | Sponsor / business decision |
| NCT02826161 | A Study of Napabucasin (BBI-608) Plus Weekly Paclitaxel Versus Weekly Paclitaxel Alone in…(CanStem43L) | Phase 3 | terminated | Jul 7, 2016 | Sumitomo Pharma America, Inc. | Change of treatment landscape and evolving standard of care | Other (stated, no rule matched) |
| NCT05905341 | Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in… | Phase 1 | withdrawn | Jun 15, 2023 | Pfizer | This decision was based on business considerations and not due to specific safety reasons or a… | Safety / toxicity |
| NCT03871153 | Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in… | Phase 2 | terminated | Mar 12, 2019 | Greg Durm, MD | Investigator decided to halt study due to low accrual. | Investigator |
| NCT03995667 | Tumor Treating Fields (TTFields) Therapy to Manage Brain Metastases in Small Cell Lung… | Phase 2 | terminated | Jun 24, 2019 | OHSU Knight Cancer Institute | Low accrual | Enrollment / accrual |
| NCT03228186 | Trial of Pevonedistat Plus Docetaxel in Patients With Previously Treated Advanced… | Phase 2 | terminated | Jul 24, 2017 | University of Michigan Rogel Cancer Center | Pharmaceutical company discontinued the study drug. | Sponsor / business decision |
| NCT04308785 | A Study of Atezolizumab With or Without Tiragolumab Consolidation in Limited Stage Small… | Phase 2 | terminated | Mar 16, 2020 | Hoffmann-La Roche | The sponsor's decision was based on the negative results of SKYSCRAPER-02. | Sponsor / business decision |
| NCT05737849 | A Study to Learn About the Tests Looking for a Gene Mutation in Adults With Lung Cancer…(ELEGANT) | — | withdrawn | Feb 21, 2023 | Takeda | Business reason, unrelated to product safety | Safety / toxicity |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With… | Phase 1 / Phase 2 | withdrawn | Oct 19, 2023 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT04739358 | CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC | Phase 1 / Phase 2 | terminated | Feb 4, 2021 | Criterium, Inc. | Study was terminated due to lack of lack of enrollment and difficult patient population. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 22, 2024source: clinicaltrials